Hematologic Cancer Develops in Some Patients Receiving Eli-Cel

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 10, 2024 -- Hematologic cancer develops in some patients receiving lentiviral elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy, according to a study published in the Oct. 10 issue of the New England Journal of Medicine.

Christine N. Duncan, M.D., from Harvard Medical School in Boston, and colleagues analyzed peripheral-blood and bone marrow samples from patients with cerebral adrenoleukodystrophy who received eli-cel therapy in two completed phase 2 to 3 studies (ALD-102 [32 patients] and ALD-104 [35 patients]) and the associated ongoing follow-up study (LTF-304) to examine the risk for oncogenesis with eli-cel.

The researchers found that seven of 67 patients developed hematologic cancer after receipt of eli-cel: Myelodysplastic syndrome (MDS) with unilineage dysplasia developed in two patients at 14 and 26 months; MDS with excess blasts developed in three patients at 28, 42, and 92 months; MDS developed in one patient at 36 months; and acute myeloid leukemia developed in one patient at 57 months. Predominant clones contained lentiviral vector insertions at multiple loci in the six patients with available data. Cytopenias developed in several patients; most had vector insertions in multiple genes within the same clone. Of the seven patients, six also had somatic mutations and one had monosomy 7. Four of the five patients with MDS with excess blasts or MDS with unilineage dysplasia who underwent allogeneic hematopoietic stem cell transplantation (HSCT) remain free of MDS without recurrence of cerebral adrenoleukodystrophy symptoms.

"The risk of oncogenesis with eli-cel must be weighed against the severity and natural history of cerebral adrenoleukodystrophy as well as the availability of other treatments and their risks, including allogeneic HSCT," the authors write.

The study was funded by Bluebird Bio, the manufacturer of eli-cel.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-11 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords